CRD-750-202

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-750 in Subjects with Chronic Heart Failure with Preserved Ejection Fraction

Stage: followup
Medicine: Tovinontrine
Population: Hartfalen
Phase: II
First Patient In: 1 October 2024
Last Patient In: 23 May 2025
Last Patient Last Visit: 1 December 2025

National Lead

prof. dr. A. Voors

Cardioloog

Study Director

drs. N.Y.Y. AL Windy

Cardioloog

Office Contact

M.J. van Doorn

WCN